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Introduction: Heme oxygenase-1 (HO-1) is the rate limiting enzyme that catalyzes the 
conversion of heme into biliverdin, free iron, and carbon monoxide (CO). The first 
human case of HO-1 deficiency showed abnormalities in blood coagulation and the 
fibrinolytic system. Thus, HO-1 or HO-1 products, such as CO, might regulate 
coagulation and the fibrinolytic system. This study examined whether 
tricarbonyldichlororuthenium (II) dimer (CORM-2), which liberates CO, modulates the 
expression of tissue factor (TF) and plasminogen activator inhibitor type 1 (PAI-1) in 
human umbilical vein endothelial cells (HUVECs), and TF expression in peripheral 
blood mononuclear cells (PBMCs). Additionally, we examined the mechanism by which 
CO exerts its effects. 
Materials and Methods: HUVECs were pretreated with 50 µM CORM-2 for 3 hours, and 
stimulated with tumor necrosis factor-α (TNF-α, 10 ng/ml) for an additional 0-5 hours. 
PBMCs were pretreated with 50-100 µM CORM-2 for 1hour followed by stimulating 
with lipopolysaccharid (LPS, 10 ng/ml) for additional 0-9 hours. The mRNA and protein 
levels were determined by RT-PCR and western blotting, respectively. 
Results: Pretreatment with CORM-2 significantly inhibited TNF-α-induced TF and 
PAI-1 up-regulation in HUVECs, and LPS-induced TF expression in PBMCs. CORM-2 
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inhibited TNF-α-induced activation of p38 MAPK, ERK1/2, JNK, and NF-κB signaling 
pathways in HUVECs. 
Conclusions: CORM-2 suppresses TNF-α-induced TF and PAI-1 up-regulation, and 
MAPKs and NF-κB signaling pathways activation by TNF-α in HUVECs. CORM-2 
suppresses LPS-induced TF up-regulation in PBMCs. Therefore, we envision that the 
antithrombotic activity of CORM-2 might be used as a pharmaceutical agent for the 
treatment of various inflammatory conditions.  
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Abbreviations 
CORM-2 = tricarbonyldichlororuthenium (II) dimer 
CO = carbon monoxide 
HO-1 = heme oxygenase-1 
TF = tissue factor 
PAI-1 = plasminogen activator inhibitor type 1 
HUVECs = human umbilical vein endothelial cells 
PBMCs= Peripheral blood mononuclear cells 
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TNF-α = Tumor necrosis factor-α 
LPS=Lipopolysaccharide 
DMSO = dimethyl sulfoxide 
GAPDH = Glyceraldehyde-3-phosphate dehydrogenase 
p38MAPK = p38 mitogen-activated protein kinase 
ERK1/2 = extracellular signal-regulated kinase1/2 
JNK = c-Jun N-terminal kinase 
NF-κB = nuclear factor-kappa B 













Heme oxygenase-1 (HO-1), the inducible isoform of heme oxygenase that catalyzes the 
formation of carbon monoxide (CO), biliverdin/bilirubin, and ferrous iron, is induced 
under conditions of oxidative stress and inflammation [1]. Recent analyses of HO-1 
knockout mice and of human HO-1 deficiency have indicated that HO-1 is an important 
molecule in the host’s defense against oxidative stress, and that HO-1 has potent 
anti-inflammatory properties [2, 3]. Moreover, Yachie A, et al. reported that the first 
human case of HO-1 deficiency showed endothelial cell injury and abnormalities in the 
coagulation/fibrinolytic system; plasma levels of the thrombin-antithrombin complex 
(TAT), plasmin-α2 plasmin inhibitor complex (PIC), and thrombomodulin were 
significantly increased, respectively [3, 4]. Therefore, HO-1 or HO-1 products, such as 
CO, may be associated with the regulation of the coagulation/fibrinolytic system. 
CO has long been known in biology and medicine as a toxic compound due to its 
ability to bind hemoglobin with a much higher affinity than oxygen [5]. Acute exposure 
to high concentrations of CO is one of the leading causes of fatal poisoning in 
industrialized countries. Despite its reputation as a toxic gas, CO endogenously 
produced by HO has essential physiological functions and is of vital importance for 
cellular hemostasis [6]. Moreover, anti-inflammatory, anti-apoptotic, anti-atherogenic, 
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and cytoprotective effects are just a few of the pharmacological actions attributed to 
exogenously applied CO in low concentrations in various models of disease [7, 8]. 
Numerous reports have demonstrated CO-dependent protection in animal models of 
inflammatory syndromes, including sepsis [9] and colitis [10]. Inhalation of CO 
significantly suppresses ischemic induction of PAI-1 expression and the accumulation of 
fibrin in mice [11]. CO provides protection in a murine model of sepsis through 
modulation of inflammatory cytokine production [12]. In addition, the absence of HO-1 
in aortic allograft recipient mice results in 100% mortality within 4 days due to arterial 
thrombosis, and CO rescues HO-1-deficient recipients from thrombosis after 
transplantation [13]. Therefore, we predict that CO will be beneficial in situations in 
which inflammation plays a damaging role. 
Transitional metal carbonyls have been identified as potential CO-releasing 
molecules (CO-RMs) with the potential to facilitate the pharmaceutical use of CO by 
delivering it to tissues and organs [14, 15]. One novel member of the CO-RMs, 
tricarbonyldichlororuthenium (II) dimer (CORM-2), liberates CO in the presence of 
dimethyl sulfoxide (DMSO) [16]. It has been reported that CORM-2 exhibits 
anti-inflammatory actions in lipopolysaccharide (LPS)-stimulated human umbilical 
vein endothelial cells (HUVECs) by decreasing LPS-induced production of reactive 
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oxygen species and nitric oxide [17]. Additionally, CORM-2 significantly suppresses 
elevated PAI-1 expression in HO-1 deficient cells [18]. In contrast, Nielsen et al. 
reported that CORM-2 significantly enhances the velocity of clot growth and strength, 
and attenuates protamine-mediated hypocoagulation/hyperfibrinolysis [19, 20]. 
CORM-2 has been recently demonstrated to diminish tissue-type plasminogen activator 
(tPA)-mediated fibrinolysis of plasma thrombi [21, 22]. Therefore, it is unclear whether 
CORM-2 has anti-inflammatory and anti-coagulation roles. 
In this study, we examined whether CORM-2 modulates the expression of TF and 
PAI-1 in HUVECs, and the expression of TF in peripheral blood mononuclear cells 
(PBMCs). In addition, we investigated whether CORM-2 affects the MAPK and NF-κB 










Materials and methods 
Materials 
CORM-2 ([Ru(CO)3Cl2]2) was obtained from Acros Organics (Geel, Belgium) and 
solubilized in DMSO. Inactive forms was Ru(DMSO)4Cl2 (iCORM-2), a molecule where 
the carbonyl groups have been replaced with DMSO. Tumor necrosis factor-α (TNF-α) 
was obtained from R＆D systems (Minneapolis, MN, USA) and dissolved in 
0.2-μm-filtered phosphate-buffered saline (PBS) + 1% Bovine serum albumin (BSA). 
SB203580, U0126, and SP600125 were purchased from Alexis Biochemicals Inc (San 
Diego, CA) and dissolved in DMSO. Anti-TF, Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), p38 mitogen-activated protein kinase (p38 MAPK), 
extracellular signal-regulated kinase1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), 
phosho-p38 MAPK, phospho-ERK1/2, phospho-JNK, nuclear factor-kappa B (NF-κB, 
p65), IκBα, and Oct-1 polyclonal antibodies were purchased from Santa Cruz 
Biotechnology Inc (CA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was obtained from Nacalai Tesque Inc (Kyoto, Japan). 
 
Cell Culture 
HUVECs and associated medium, EGM-2 Bullet Kit, were purchased from TaKaRa 
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Bio Inc (Otsu, Japan). HUVECs were grown to confluence in EGM-2 that contained 2% 
fetal bovine serum at 37 ℃ in humidified atmosphere of 5% CO2. The cells in this 
experiment were used within 3 to 8 passages. Cells were pretreated with CORM-2 (50 
μM) for 3 hours followed by stimulating with TNF-α (10 ng/ml) for additional 0-5 hours. 
CORM-2 was dissolved in DMSO and then diluted in culture medium (0.05 % v/v, pH = 
7.6). Cells were treated with 0.05 % DMSO (CORM-2 vehicle). Experiments were 
repeated with the negative controls iCORM-2 to assess whether the effects observed 
were due to the CO liberated by CORM-2 or caused by other components of the 
molecules. After stimulation, the cells were harvested separately. 
PBMCs were isolated from heparinized peripheral blood by a density gradient 
centrifugation with Lymphoprep (Axis Shield, Oslo, Norway). PBMCs were suspended 
in RPMI 1640 medium (Invitrogen, California, USA). PBMCs were pretreated with 
50-100 µM CORM-2 for 1 hour followed by stimulating with 10 ng/ml LPS for additional 
0-9 hours.  
Quantification of RNA 
Total RNA was extracted from cultured cells by using Nucleo SpinⓇ(NIPPON 
Genetics Inc, Tokyo, Japan). The cDNA was synthesized from total RNA by reverse 
transcription with the PrimeScript® RT-PCR Kit (TaKaRa Bio Inc, Otsu, Japan) 
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according to the manufacturer’s instructions. The cDNA was subjected to the following 
PCR conditions: 30 cycles of denaturation at 94℃ for 30 s, annealing at 55℃ for 30 s 
and extension at 72℃ for 30 s. The primers used in the reactions showed in Table1. 
PCR products were subjected to electrophoresis in 3 % agarose gel and densitometry 
was performed using Typhoon9200 (GE Healthcare Inc, Tokyo, Japan). Levels of mRNA 
were normalized to the concentration of GAPDH mRNA. 
 
Separation of cytosol and nuclear extract 
To separate nuclear and cytoplasmic protein fractions, cells were washed with cold 
PBS, lysed in buffer A (120 mM KCl, 20 mM Tris-HCl (pH 7.9), 2 mM EDTA, 1 mM 
dithiothreitol (DTT)) and incubated for 5 min on ice. Samples were centrifuged at 4℃ 
for 1 min at 10000 rpm. Remove supernatant and add buffer B (120 mM KCl, 20 mM 
Tris-HCl (pH 7.9), 2 mM EDTA, 1 mM DTT, 0.4% NonidetP-40, protease inhibitor 
cocktail solution (Roche Molecular Biochemicals)) to cells and incubate for 10 min on ice. 
The supernatant (cytosol extract) was obtained by centrifugation at 10000 rpm for 30 s. 
The pellets (nuclei) were resuspended in 200 µl of buffer C (120 mM KCl, 20 mM 
Tris-HCl (pH 7.9), 2 mM EDTA, 1 mM DTT, protease inhibitor cocktail solution) and 
centrifuged at 10000 rpm for 30 s at 4℃. The nuclei were then extracted in 20 µl of 
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buffer D (40 mM Tris-HCl (pH7.9), 0.8 M NaCl, 3 mM EDTA, 50% glycerol, 1 mM DTT, 
protease inhibitor cocktail solution) and incubated on ice for 15 min. Finally, the 
samples were centrifuged for 6 min at 15000 rpm, and the supernatants were collected 
and saved as the nuclear protein fraction. Samples were stored at -80℃. 
 
Western bolt analysis 
HUVECs were lysed in buffer comprising 50 mM Tris-HCl, pH7.5, 1 % BSA, 2 mM 
EDTA, 100 U/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin and 200 mM 
phenylmethanesulfonyl fluoride. Samples of cell lysate were electrophoresed on 10 % 
SDS/polyacrylamide gel, and transferred to nitrocellulose membrane Hypond™-P (GE 
Healthcare Inc, Tokyo, Japan). After being transferred to membranes, the samples were 
immunoblotted with primary antibodies, followed by secondary antibodies conjugated 
with horseradish peroxidase. The protein bands were detected with Immobilon Western 
HRP Detection Substrate (Nihon Millipore Inc, Tokyo, Japan). 
 
Cell viability using MTT assay 
Cells were plated into the wells of 96-well microplates (Falcon, Becton Dickinson, 
NJ, USA). After incubation with or without CORM-2 or TNF-α, medium was changed to 
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normal culture medium. For cell viability assay, 10 μl of sterile, filtered MTT stock 
solutions in PBS (5 mg/ml) was added to each well. After three hours, the unreacted dye 
was removed, and the formazan crystals were dissolved with 150 μl of DMSO. After 
gentle agitation for five minutes, the absorbance was read at 570 nm using Microplate 
Reader (Tecan, Kanagawa, Japan). Cells incubated without treatment were considered 
as controls, and cell viability values were set at 100 %. 
 
Statistical analysis 
The mRNA expression data represent the mean ± SD of five independent 
experiments. Western blot image is representative of three different blots. Statistical 
analysis was performed using one-way ANOVA combined with Bonferroni test. A value 










Pretreatment with CORM-2 suppressed TF and PAI-1 expression in TNF-α-stimulated 
HUVECs and TF expression in LPS -stimulated PBMCs.  
After TNF-α stimulation, TF mRNA levels were approximately 6-fold (Fig 1B, 
p<0.05) and PAI-1 mRNA levels were approximately 2-fold (Fig. 1D, p<0.05) increased 
as compared to the control. Pretreatment of HUVECs with CORM-2 significantly 
decreased TF mRNA levels (approximately 80% suppression, p<0.05) (Fig. 1B), and 
PAI-1 mRNA levels (approximately 60% suppression, p<0.05) (Fig. 1D) as compared to 
the TNF-α-stimulated group. Similar to mRNA expression, pretreatment with CORM-2 
inhibited TNF-α-induced TF and PAI-1 protein up-regulation (Fig. 1A and C). On the 
other hand, iCORM-2, which does not liberate CO, had no effect on TF and PAI-1 mRNA 
expression (Fig. 1B and D). Incubation with 50 µM CORM-2 or iCORM-2 did not affect 
cell viability according to MTT assays (data not shown). 
In PBMCs, LPS increased approximately 10-fold TF mRNA expression (Fig. 2B, 
p<0.05). Pretreatment with CORM-2 significantly inhibited LPS-induced TF mRNA 
expression (50 μM: approximately 70% suppression, 100 µM; approximately 80% 
suppression, p<0.05 respectively) (Fig. 2B). Similarly to the mRNA expression, CORM-2 
did not affect TF protein expression. CORM-2 significantly suppressed TF protein 
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expression induced by LPS (Fig. 2A). 
 
Pretreatment with CORM-2 suppressed TNF-α stimulated Mitogen-activated protein 
kinases (MAPKs) Phosphorylation. 
To determine whether pretreatment with CORM-2 affected MAPKs 
phosphorylation, the phosphorylation of p38 MAPK, ERK1/2, and JNK were assessed 
after TNF-α stimulation. TNF-α induced a transient phosphorylation of p38 MAPK and 
JNK, with maximal activation occurring after 10 min of stimulation. Additionally, 
TNF-α induced transient phosphorylation of ERK1/2 with maximal activation occurring 
after 30 min of stimulation (Fig. 3). On the other hand, pretreatment of CORM-2 
inhibited phosphorylation of p38 MAPK, ERK1/2, and JNK (Fig. 3). Total expression of 
p38 MAPK, ERK1/2, and JNK remained unaffected at all time points examined. 
 
MAPK Inhibitors Affected TNF-α-induced TF and PAI-1 Protein Expression 
To confirm the role of p38 MAPK, ERK, or JNK in the repression of TF and PAI-1 
expression by CORM-2, HUVECs were pre-incubated with p38 MAPK inhibitor 
(SB203580, 20 µM), ERK1/2 inhibitor (U0126, 20 µM), or JNK inhibitor (SP600125, 20 
µM) for 1 hour each. HUVECs were stimulated with 10 ng/ml TNF-α, and TF and PAI-1 
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protein expressions were analyzed by western blots. The p38 MAPK inhibitor, 
SB203580, and JNK inhibitor, SP600125, strongly inhibited TNF-α-induced TF protein 
up-regulation. In contrast, the ERK1/2 inhibitor U0126 did not inhibit TNF-α-induced 
TF protein up-regulation (Fig. 4). TNF-α-induced PAI-1 protein up-regulation was 
suppressed by the p38 MAPK inhibitor, ERK inhibitor, and JNK inhibitor (Fig. 4). 
 
Pretreatment with CORM-2 Inhibited NF-κB Activation in TNF-α-stimulated HUVECs. 
To determine whether pretreatment with CORM-2 could inhibit NF-κB 
transcriptional activation, nuclear NF-κB (p65) was detected by western blot. Moreover, 
IκBα and phosphorylated IκBα in cytosolic extracts were determined by western blots. 
TNF-α promoted translocation of NF-κB (p65) into the nucleus (Fig. 5B). In contrast, 
pretreatment with CORM-2 reduced NF-κB (p65) translocation to the nucleus after 
TNF-α stimulation (Fig. 5B). Although TNF-α induced IκBα degradation and 
phosphorylation of IκBα, pretreatment with CORM-2 inhibited TNF-α-induced 







We demonstrated that CORM-2 suppresses TNF-α-induced TF and PAI-1 
up-regulation in HUVECs and LPS-induced TF up-regulation in PBMCs. Additionally, 
pretreatment with CORM-2 suppressed MAPKs and NF-κB signaling pathways 
activation by TNF-α. Thus, we suggest that CORM-2 might provide a therapeutic 
avenue for the hypercoagulable state associated with inflammation diseases. 
TF combines with factor VIIa to activate factor X leading to thrombosis. The 
majority of cases of systemic inflammatory response syndrome, disseminated 
intravascular coagulation, and sepsis are accompanied by hyperactivation of TF in 
circulating monocytes and damaged tissue. Induction of TF expression on monocytes 
and endothelial cells is central to the development of septic coagulopathy. Early 
modulation of TF activity is presently a therapeutic strategy in systemic inflammatory 
response syndrome patients [23]. On the other hand, PAI-1 plays an important role in 
the regulation of fibrinolysis and proteolysis by inhibiting tissue-type plasminogen 
activator and urokinase-type plasminogen activator [24]. Studies in animal models have 
indicated that increased PAI-1 activity enhances thrombosis, and antibodies against 
PAI-1 prevent the progression of thrombosis [25]. Our study showed that pretreatment 
with CORM-2 suppresses the TNF-α-induced TF and PAI-1 up-regulation in HUVECs. 
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Furthermore, we showed that LPS-induced TF mRNA and protein up-regulation on 
PBMCs were significantly inhibited by CORM-2. The negative control (iCORM-2), 
which does not liberate CO, did not affect TF and PAI-1 expression. Therefore, CO 
released from CORM-2 might inhibit TNF-α-induced TF and PAI-1 expression in 
HUVECs and LPS- induced TF expression in PBMCs.  
MAPKs constitute a family of proline-directed serine/threonine kinases that 
include at least three distinct cascades: p38 MAPK, ERK, and JNK. MAPKs function as 
cellular signal transducers, and play a central role in the control of cellular proliferation, 
the production of inflammatory cytokines [26, 27], and regulating TF and PAI-1 
expression [28, 29]. In our study, phosphorylation of p38 MAPK, ERK1/2, and JNK 
enhanced by TNF-α and pretreatment with CORM-2 suppressed phosphorylation of p38 
MAPK, ERK1/2, and JNK. The p38 MAPK and JNK inhibitors strongly inhibited 
TNF-α-induced TF and PAI-1 protein up-regulation. The ERK1/2 inhibitor suppressed 
TNF-α-induced PAI-1 protein up-regulation, but did not inhibit TF protein 
up-regulation. A previous study indicated that pretreatment of HUVECs with an ERK 
inhibitor (U0126, 10 µM) did not significantly inhibit TF induction by TNF-α [30]. In 
contrast, another study showed that ERK activation by TNF-α increased TF expression 
in endothelial cells [31]. Further studies may be necessary to examine whether ERK1/2 
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activation induces TF expression in HUVECs using dominant negative mutants of 
ERK1/2. 
NF-κB is a rapidly acting transcription factor involved in inflammatory reactions 
and coagulation/fibrinolytic systems; it regulates the expression of cytokines, TF, and 
PAI-1 [27, 32]. NF-κB is a heterodimer composed primarily of a 50 kDa DNA binding 
subunit and a 65 kDa transactivator (p65 or Rel A). NF-κB is retained in the cytoplasm 
associated with a family of inhibitory proteins termed IκB. In response to inflammatory 
stimuli such as TNF-α and LPS, the IκBs are rapidly phosphorylated, releasing NF-κB 
and undergoing ubiquitination and proteolysis by the 26S proteosome [33]. In the 
present study, TNF-α induced translocation of NF-κB (p65) into the nucleus. In contrast, 
pretreatment with CORM-2 suppressed TNF-α induced NF-κB translocation to the 
nucleus. Thus, we consider that pretreatment with CORM-2 might suppress 
TNF-α-induced TF and PAI-1 up-regulation via regulating TNF-α signaling pathways in 
HUVECs. 
It has been reported that CORM-2 and CO confer anti-inflammatory effects by 
interfering with NF-κB activation [12, 34]. On the other hand, inhalation of CO for 1 h 
has no anti-inflammatory effects in a systemic inflammation model in humans [35]. 
CORM-2 increases the velocity of thrombus growth and strength in hemophilia A, 
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hemophilia B, and factor VII-deficient plasmas [36]. Furthermore, CORM-2 enhances 
coagulation and markedly attenuates fibrinolysis in human plasma [37]. In contrast, 
enhanced induction of HO-1 and the administration of CORM-2 inhibit thrombus 
formation and affect the protein C system in sepsis [38]. CORM-2 reduces HMGB1 
release in macrophages and septic animal models [9, 39]. Our study showed that 
CORM-2 moderates TNF-α-induced TF and PAI-1 up-regulation. We consider that 
CORM-2 might have benefit in situations in which inflammation plays a damaging role. 
However, acute exposure to high concentrations of CO is one of the leading causes of 
fatal poisoning in industrialized countries. Further research is thus needed to 
understand the effect of CORM-2 in inflammatory states. Whether direct application of 
CO by pharmacologic administration in humans will provide a safe and effective 
modality for treatment of human diseases is not yet known. We believe that further 
research is needed to understand the pharmacokinetics and toxicology of CO application 
in humans. 
In conclusion, our study indicated that pretreatment of CORM-2, a CO-releasing 
molecule, suppresses TNF-α-induced TF and PAI-1 up-regulation in HUVECs, and 
LPS-induced TF up-regulation in PBMCs. CORM-2 regulates the activation of MAPKs 
and NF-κB signaling pathways. Therefore, we suggest that CORM-2 could constitute a 
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novel anti-coagulative therapy in various inflammatory diseases. 
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Figures and Legends 
Figure 1 Effects of pretreatment with CORM-2 on TF and PAI-1 expression in 
TNF-α-stimulated HUVECs. HUVECs were pretreated with CORM-2 at a 
concentration of 50 µM for 3 h, and stimulated with 10 ng/ml TNF-α for additional 0-5 h. 
TF (A) and PAI-1(C) mRNA levels were determined by RT-PCR. TF (B) and PAI-1 (D) 
protein levels were analyzed by western blotting. All values are expressed as means ± 
SD (n=5).  
 
Figure 2 Effects of pretreatment with CORM-2 on TF expression in LPS-stimulated 
PBMCs. PBMCs were pretreated with CORM-2 at concentration of 50 -100 µM for 3 h, 
and stimulated with 10 ng/ml LPS for additional 0-9 h. (A) TF protein levels were 
analyzed by western blotting. (B) TF mRNA levels were determined by RT-PCR. All 
values are expressed as means ± SD (n=5). 
 
Figure 3 Effects of pretreatment with CORM-2 on TNF-α stimulated mitogen-activated 
protein kinases (MAPKs) phosphorylation. HUVECs were pretreated with CORM-2 at a 
concentration of 50 µM for 3 h, and stimulated with 10 ng/ml TNF-α for additional 0-1 h. 
Phosphorylations of p38 MAPK, ERK1/2, and JNK were analyzed by western blots. A 
 30 
 
representative image from three experiments is shown. 
 
Figure 4 Effects of MAPK inhibitors on TF and PAI-1 protein expression in 
TNF-α-stimulated HUVECs. HUVECs were pre-incubated with p38 MAPK inhibitor 
SB203580 (20 µM), ERK1/2 inhibitor U0126 (20 µM), or JNK inhibitor SP600125 (20 
µM) for 1 h and then stimulated with TNF-α for 5 h. TF and PAI-1 protein expression 
were analyzed by western blots. A representative image from three experiments is 
shown. Control: unstimulated cells. 
 
Figure 5 Effect of CORM-2 pretreatment on NF-kB activation in TNF-α stimulated 
HUVECs. HUVECs were pretreated with CORM-2 at a concentration of 50 µM for 3 h, 
and stimulated with 10 ng/ml TNF-α for an additional 0-5 h. Nuclear and cytoplasmic 
proteins of HUVEC were extracted. (A) Nuclear NF-κB (p65) was detected by western 
blot. (B) IκBα and phosphorylated IκBα in cytosolic extracts were determined by 
western blots. A representative image from three experiments is shown. 
 
 
Gene Forward Primer Sequence (5’-3’) Reverse Primer Sequence  (5’-3’) 
TF CTCGGACAGCCAACAATTCAGAGT TGTTCGGGAGGGAATCACTGCTTGAACACT 
PAI-1 GAGGTGCCTCTCTCTGCCCTCACCAACATT AGCCTGAAACTGTCTGAACATGTCG 
GAPDH CGTCATGGGTGTGAACCATGAGAAG GCATGGACTGTGGTCATGAGTCCTT 
Table1 Sequences of oligonucleotide primers used for polymerase chain reaction. 
TF: tissue factor, PAI-1: plasminogen activator inhibitor type 1  






































































Figure 1 Effects of pretreatment with CORM-2 on TF  and PAI-1 expression in TNF-α-stimulated 
HUVECs. 
TNF-α －  － － ＋  ＋ ＋ 
CORM-2 －  ＋ － －  ＋ － 
iCORM-2 －  － ＋ －  － ＋ 
TNF-α －  － ＋   ＋ 
CORM-2 －  ＋ －   ＋ 
     TNF-α －  － ＋   ＋ 







TNF-α －  － － ＋  ＋ ＋ 
CORM-2 －  ＋ － －  ＋ － 



































Figure 2 Effects of pretreatment with CORM-2 on TF expression in LPS-stimulated PBMCs. 
(A) 
(B) 
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Figure 3 Effects of pretreatment with CORM-2 on TNF-α stimulated mitogen-activated protein kinases 
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Figure 5 Effect of CORM-2 pretreatment on NF-κB activation in TNF-α stimulated HUVECs 
